Sarepta falls after notifying of patient death following treatment with Elevidys
Therapeutics are down 24.95, or 25%, to $76.40 in pre-market trading after the company shared a safety update related ...
Gene-Therapy Maker Sarepta Tanks After Patient Death
Shares of Sarepta Therapeutics have struggled for the past year due to concerns about the commercial potential of its gene ...
Sarepta’s stock slammed after patient dies of liver failure. Here’s what Wall Street is saying.
The company said that more than 800 people have been treated with Elevidys, with only one experiencing liver failure.
Sarepta reports teen death after gene therapy treatment
Sarepta Therapeutics said on Tuesday a 16-year-old boy has died due to acute liver failure, months after he received the company's U.S-approved gene therapy for a rare muscular dystrophy. The patient ...
Sarepta Therapeutics Hits 52-Week Low After Patient Death
Shares of Sarepta Therapeutics fell after the company said a patient with Duchenne muscular dystrophy died of liver failure after using its Elevidys treatment. The stock opened the market down 22% at ...
Sarepta says teen died after its gene therapy treatment
Sarepta Therapeutics said on Tuesday that a 16-year-old boy died from acute liver failure months after receiving the company's U.S-approved gene therapy for a rare muscular dystrophy. The patient ...
BofA says Elevidys risk-reward favorable despite Sarepta report of patient death
After Sarepta (SRPT) reported the death of a Duchenne muscular dystrophy patient following treatment with Elevidys after suffering acute liver ...
Investor's Business Daily on MSN12h
Sarepta's 20% Sell-Off Is 'Overblown,' 'Overdone' And 'Overly Bearish.' Here's Why It Happened.
Sarepta stock crashed Tuesday after a patient who received its approved gene therapy, Elevidys, died due to acute liver failure.